Since BIRC3 expression increased in response to standard therapy for GBM (TMZ/RT), we wanted to determine if this process was driven by other established upstream molecular pathway surrogates for therapeutic resistance in GBM. This evidence concerns the gene BIRC3 and glioblastoma.